Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib with Carboplatin and Etoposide in ES-SCLC
NCT01987232Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2013
- Primary completion
- Aug 2016
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of carfilzomib in small cell lung cancer (SCLC), sponsored by Amgen. Started Nov 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01987232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01987232.